KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Construction in Progress (2016 - 2025)

Abbott Laboratories' Construction in Progress history spans 17 years, with the latest figure at $2.6 billion for Q4 2025.

  • For Q4 2025, Construction in Progress rose 3.18% year-over-year to $2.6 billion; the TTM value through Dec 2025 reached $2.6 billion, up 3.18%, while the annual FY2025 figure was $2.6 billion, 3.18% up from the prior year.
  • Construction in Progress for Q4 2025 was $2.6 billion at Abbott Laboratories, up from $2.5 billion in the prior quarter.
  • Across five years, Construction in Progress topped out at $2.6 billion in Q4 2025 and bottomed at $1.3 billion in Q4 2021.
  • The 5-year median for Construction in Progress is $2.1 billion (2023), against an average of $2.0 billion.
  • The largest annual shift saw Construction in Progress decreased 3.91% in 2021 before it skyrocketed 39.08% in 2023.
  • A 5-year view of Construction in Progress shows it stood at $1.3 billion in 2021, then increased by 13.8% to $1.5 billion in 2022, then surged by 39.08% to $2.1 billion in 2023, then rose by 20.54% to $2.5 billion in 2024, then rose by 3.18% to $2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Construction in Progress are $2.6 billion (Q4 2025), $2.5 billion (Q4 2024), and $2.1 billion (Q4 2023).